Back to results
US 2020/0263159 A1Published application
Compositions and methods for using engineered deubiquitinases for probing ubiquitin-dependent cellular processes
AssigneeThe Trustees of Columbia University in the City of New York
InventorsHenry M. Colecraft, Scott Kanner
Life of this patent
Estimating the term…
Abstract
The present disclosure provides, inter alia, a recombinant engineered deubiquitinase (DUB) and methods for treating or ameliorating an inherited ion channelopathy, such as long QT syndrome, Brugada syndrome, or cystic fibrosis, in a subject. Further provided are methods for screening mutations causing such inherited ion channelopathies for a trafficking-deficient mutation that is treatable by the recombinant engineered DUB disclosed herein.
Claims33
A recombinant engineered deubiquitinase (DUB) comprising:
- a) a catalytic unit;
- b) a protein binder;
- and
- c) a variable linker between the catalytic unit and the protein binder.
1 more element
Dependencies are inferred from the claim text.